DOP2008000021A - Composicion farmaceutica en la forma de polvos encapsulados que comprende orlistat, procedimiento de preparacion de la composicion y su uso para el tratamiento de la obesidad - Google Patents

Composicion farmaceutica en la forma de polvos encapsulados que comprende orlistat, procedimiento de preparacion de la composicion y su uso para el tratamiento de la obesidad

Info

Publication number: DOP2008000021A
Authority: DO; Dominican Republic
Prior art keywords: agent; orlistat; pharmaceutical composition; composition; obesity
Prior art date: 2007-08-06

Application number

DO2008000021A

Other languages

English (en)

Spanish (es)

Inventor

Urzua Marcos Morales

Shu Chen Chen

Apablaza Marianela Beltran

Original Assignee

Andromaco Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-06

Filing date

2008-04-10

Publication date

2009-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51359501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2008000021(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-04-10 Application filed by Andromaco Lab filed Critical Andromaco Lab

2009-11-30 Publication of DOP2008000021A publication Critical patent/DOP2008000021A/es

Links

239000000203 mixture Substances 0.000 title abstract 8
238000000034 method Methods 0.000 title abstract 3
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title abstract 3
229960001243 orlistat Drugs 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
208000008589 Obesity Diseases 0.000 title abstract 2
235000020824 obesity Nutrition 0.000 title abstract 2
239000000843 powder Substances 0.000 title abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 4
239000006096 absorbing agent Substances 0.000 abstract 2
238000010790 dilution Methods 0.000 abstract 2
239000012895 dilution Substances 0.000 abstract 2
239000007884 disintegrant Substances 0.000 abstract 2
239000004094 surface-active agent Substances 0.000 abstract 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
108010010803 Gelatin Proteins 0.000 abstract 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
229920000159 gelatin Polymers 0.000 abstract 1
239000008273 gelatin Substances 0.000 abstract 1
235000019322 gelatine Nutrition 0.000 abstract 1
235000011852 gelatine desserts Nutrition 0.000 abstract 1
239000004615 ingredient Substances 0.000 abstract 1
239000008101 lactose Substances 0.000 abstract 1
239000000314 lubricant Substances 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
239000008108 microcrystalline cellulose Substances 0.000 abstract 1
229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
229940057838 polyethylene glycol 4000 Drugs 0.000 abstract 1
235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
229940079832 sodium starch glycolate Drugs 0.000 abstract 1
239000008109 sodium starch glycolate Substances 0.000 abstract 1
229920003109 sodium starch glycolate Polymers 0.000 abstract 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

DO2008000021A 2007-08-06 2008-04-10 Composicion farmaceutica en la forma de polvos encapsulados que comprende orlistat, procedimiento de preparacion de la composicion y su uso para el tratamiento de la obesidad DOP2008000021A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CL2007002287A CL53426B (lt)	2007-08-06	2007-08-06

Publications (1)

Publication Number	Publication Date
DOP2008000021A true DOP2008000021A (es)	2009-11-30

Family

ID=51359501

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DO2008000021A DOP2008000021A (es)	2007-08-06	2008-04-10	Composicion farmaceutica en la forma de polvos encapsulados que comprende orlistat, procedimiento de preparacion de la composicion y su uso para el tratamiento de la obesidad

Country Status (7)

Country	Link
CL (1)	CL53426B (lt)
CR (1)	CR10132A (lt)
DO (1)	DOP2008000021A (lt)
MX (1)	MX2008010082A (lt)
PA (1)	PA8786701A1 (lt)
PE (1)	PE20091224A1 (lt)
SV (1)	SV2009002991A (lt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL216542B1 (pl) *	2008-03-20	2014-04-30	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku

2007
- 2007-08-06 CL CL2007002287A patent/CL53426B/es active
- 2007-10-25 PE PE2007001452A patent/PE20091224A1/es active IP Right Grant
2008
- 2008-04-10 DO DO2008000021A patent/DOP2008000021A/es unknown
- 2008-07-01 PA PA20088786701A patent/PA8786701A1/es unknown
- 2008-07-07 CR CR10132A patent/CR10132A/es not_active Application Discontinuation
- 2008-07-31 SV SV2008002991A patent/SV2009002991A/es unknown
- 2008-08-06 MX MX2008010082A patent/MX2008010082A/es active IP Right Grant

Also Published As

Publication number	Publication date
MX2008010082A (es)	2009-04-17
CL2007002287A1 (lt)	2007-12-14
CR10132A (es)	2008-10-28
CL53426B (lt)	2016-11-28
PE20091224A1 (es)	2009-08-26
PA8786701A1 (es)	2009-04-23
SV2009002991A (es)	2009-04-16

Similar Documents

Publication	Publication Date	Title
BRPI0713777B8 (pt)	2021-05-25	processo para preparação de formulações de pó seco de um sal de glicopirrônio para inalação
MX2013006158A (es)	2014-03-21	Granulos de dispersion rapida, comprimidos de disolucion oral y metodos.
ES2923214T3 (es)	2022-09-26	Composición farmacéutica que comprende mesilato de lenvatinib
BRPI0606332A2 (pt)	2009-11-17	composição farmacêutica de bendamustina, preparação liofilizada, forma de dosagem farmacêutica, método para obter aprovação oficial para um produto de bendamustina, processo para fabricar uma preparação liofilizada de bendamustina, solução ou dispersão de pré-liofilização de bendamustina, pó liofilizado, método para preparar uma preparação liofilizada de bendamustina, formulação para liofilização, e, uso de uma solução farmaceuticamente aceitável
BRPI0709847B8 (pt)	2021-05-25	composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio
CO6720961A2 (es)	2013-07-31	Imidazopiridazinas sustituidas
IS8669A (is)	2007-08-15	Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í
AR077190A1 (es)	2011-08-10	Composiciones y metodos para preparar composiciones inmunogenicas conjugadas de polisacaridos capsulares de staphylococcus aureus de los serotipos 5 y 8
NZ599594A (en)	2014-06-27	Fast dissolving solid dosage form
UY37952A (es)	2019-05-31	Formulaciones de un inhibidor de la quinasa trk macrocíclica
HRP20200055T1 (hr)	2020-04-03	Eutektičke formulacije ciklobenzaprin-klorovodika i manitola
CO6761350A2 (es)	2013-09-30	Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
FI4066821T3 (fi)	2025-05-13	Neratinibimaleaatin tablettiformulaatioita
HRP20140876T1 (hr)	2014-10-24	Rifaksimin u prahu, postupak za dobivanje istog i pripravci sa kontroliranim oslobađanjem koji sadrže navedeni rifaksimin te koji su korisni za dobivanje dugotrajnog djelovanja
AR111570A1 (es)	2019-07-31	Composición farmacéutica que comprende selexipag
WO2008127358A3 (en)	2008-12-24	Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
UY29410A1 (es)	2006-10-31	Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
BR112021019104A2 (pt)	2021-11-30	Micropartículas secas
BR112015029773A2 (pt)	2017-07-25	pós revestidos com aroma
PH12020551412A1 (en)	2021-09-01	Pharmaceutical composition including sodium alkyl sulfate
PE20151024A1 (es)	2015-07-27	Composicion farmaceutica novedosa
HRP20191217T1 (hr)	2019-10-18	Čvrsti farmaceutski sastav citizina i postupak pripreme istog
MY209656A (en)	2025-07-29	Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
BR112018074381A2 (pt)	2019-03-06	[8-(fenil sulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il] (1h-1,2,3-triazol-4-il)metanonas
ES2922903T3 (es)	2022-09-21	Composición farmacéutica que comprende sales de lenvatinib